welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.
expertly curated content related to this topic
- Peter Mattei, MDEducation: MD - Harvard Medical School,...
- Lisa A. Boardman, MDDr. Lisa Boardman is an Assistant Profes...
- Vanderbilt University Medical CenterSpeciality ClinicPatient Resources: ...
- Jennifer Siettmann, MS, GCJennifer Siettmann is a cancer genetic c...
- John NickelsJohn Nickels is a member of FAP Gene Su...
- polyposis (polypeople)FAP is an inherited condition which main...
- Ann Bastian, MSGenetic CounselorShe worked as a gen...